RPRX
Royalty Pharma Plc
57.70$
-1.5%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +3.3% | -1.5% | +9.5% | +2.2% | +1.0% | -3.4% | +4.1% | +5.6% | +1.4% | +1.0% | +0.0% | |
| – | -26.3% | +22.4% | +65.4% | -30.4% | +0.4% | +2.3% | -17.5% | +21.7% | -66.5% | +130.3% | -43.0% | |
| – | -49.1% | +76.7% | +109.3% | -46.2% | -2.2% | +17.1% | -41.9% | +48.6% | -34.1% | -5.3% | +38.5% | |
| – | -26.7% | +24.2% | +66.6% | -30.9% | +0.4% | +2.6% | -18.1% | -35.8% | -33.2% | -4.6% | +37.6% | |
| – | -40.9% | -0.8% | +6.1% | +5.6% | +8.3% | -11.8% | +16.6% | +3,104.3% | -0.6% | -8.6% | +10.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | +0.0% | +0.0% | +0.0% | -0.1% | |
| – | -89.1% | – | – | +281,096.2% | – | – | – | -100.0% | – | – | – | |
| – | +0.4% | -0.5% | +26.1% | -1.5% | +1.2% | -0.8% | +12.8% | +10.3% | +1.8% | -0.3% | +1.6% | |
| – | +26.1% | -22.8% | +121.3% | +323.6% | +7.4% | -5.6% | +2.0% | -56.0% | +19.9% | -15.8% | +17.8% | |
| – | – | – | – | – | +0.1% | +0.1% | +0.1% | -61.7% | -0.8% | +0.0% | +0.0% | |
| – | +11.3% | -23.8% | +102.7% | -5.8% | -39.4% | +181.5% | -46.3% | +104.9% | -53.1% | +31.3% | +39.6% | |
| – | +0.1% | +0.1% | +23.8% | -13.0% | +0.1% | +0.1% | +5.8% | +22.3% | +0.1% | +0.1% | +0.1% | |
| – | +6.3% | -0.4% | -0.4% | +6.1% | +1.1% | -3.7% | -5.1% | +1.0% | +1.0% | +6.4% | -0.8% | |
| – | +17.9% | -3.6% | -2.0% | +16.2% | +2.9% | -12.8% | -10.4% | +3.7% | +2.3% | +6.4% | -1.9% | |
| – | +0.1% | -0.8% | -0.1% | -0.7% | -0.7% | -1.9% | -2.7% | -0.5% | +0.0% | +0.0% | -0.5% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.